2′,3′,5′-Tri-O-acetyluridine CAS 4105-38-8
Identification
CAS Number
4105-38-8
Name
2′,3′,5′-Tri-O-acetyluridine
Synonyms
2′,3′,5′-Triacetyluridine
223-881-5
[EINECS]
2WP61F175M
[UNII]
2′,3′,5-TRI-ACETYLURIDINE
2′,3′,5′-Tri-O-acetyluridin
[German]
[IUPAC name – generated by ACD/Name]
2′,3′,5′-Tri-O-acetyluridine
[IUPAC name – generated by ACD/Name]
2′,3′,5′-Tri-O-acétyluridine
[French]
[IUPAC name – generated by ACD/Name]
2′,3′,5′-triacetate uridine
2′,3′,5′-Triacetyluridine
4105-38-8
[RN]
triacétate d’uridine
[French]
[INN]
triacetato de uridina
[Spanish]
[INN]
Uridine 2′,3′,5′-triacetate
uridine triacetate
[INN]
[USAN]
Uridine, 2′,3′,5′-triacetate
[Index name – generated by ACD/Name]
uridini triacetas
[Latin]
[INN]
Vistogard
[Trade name]
Xuriden
[Trade name]
SMILES
CC(=O)OC[C@H]1OC@@HC@H[C@@H]1OC(C)=O
StdInChI
InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1
StdInChIKey
AUFUWRKPQLGTGF-FMKGYKFTSA-N
Molecular Formula
C15H18N2O9
Molecular Weight
370.319
EINECS
223-881-5
MDL Number
MFCD07798677
Properties
Appearance
White or almost white crystalline powder
Safety Data
RIDADR
NONH for all modes of transport
Specifications and Other Information of Our 2′,3′,5′-Tri-O-acetyluridine CAS 4105-38-8
Identification Methods
HNMR, HPLC
Purity
≥98%
Heavy Metals(As Pb)
≤0.002%
Loss on Drying
≤1.0%
Residue on Ignition
≤0.20%
Shelf Life
3 years
Storage
Store at room temperature, Sealed and away from light.
Known Application
1. Treatment of Hereditary Orotic Aciduria This product is an orphan drug indicated for the treatment of the rare genetic disorder, hereditary orotic aciduria. It functions by replenishing endogenous uridine levels, correcting metabolic disturbances, and ameliorating associated hematopoietic and growth abnormalities in patients. 2. Chemotherapy Antidote Specifically indicated for the management of toxicity resulting from overdoses of the chemotherapeutic agents 5-fluorouracil and capecitabine. It serves to alleviate severe adverse effects induced by chemotherapy, including cardiac, neurological, and gastrointestinal toxicities, as well as neutropenia.
Links
This product is developed by our R&D company Caming Pharmaceutical Ltd (https://www.caming.com/).
This product is developed by our R&D company Watson International Ltd (https://www.watson-int.com/).